Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 5 versus PARACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 5 versus PARACORT.
DEXONE 0.5 vs PARACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Paracort is a corticosteroid that acts by binding to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines and prostaglandins.
0.5 mg orally once daily, with gradual taper to lowest effective dose
Prednisone 5-60 mg orally once daily; initial dose 5-15 mg daily; for acute conditions, up to 60 mg daily tapered over 2-3 weeks.
None Documented
None Documented
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Terminal elimination half-life is 3.5 hours (range 2.5–4.5 hours) in adults with normal renal function; prolonged to up to 10–15 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Renal elimination of unchanged drug accounts for approximately 70% of the dose; biliary/fecal excretion accounts for 20%; the remainder is metabolized and excreted as inactive metabolites.
Category C
Category C
Corticosteroid
Corticosteroid